e-Therapeutics plc Appointment of Director (1796V)

TIDMETX

RNS Number : 1796V

e-Therapeutics plc

01 November 2017

e-Therapeutics

('e-Therapeutics' or the 'Company')

Appointment of Director

Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine Soden as non-executive director, and the retirement of Brad Hoy who has served on the e-Therapeutics Board as a non-executive director for nine years. Christine will take over from Brad Hoy as Chair of the Board's Audit & Risk Committee.

Christine Soden BSc, ACA qualified with Price Waterhouse and has extensive financial management experience in the healthcare industry, having been Group Financial Controller at Medeva plc before serving as CFO in several public healthcare companies including Optos plc, BTG plc, and Celltech Chiroscience plc. Currently Christine is CFO at Acacia Pharma Group Limited and is a non-executive director at two private biotech companies.

Iain Ross, Chairman of e-Therapeutics commented: "We are delighted to be able to welcome Christine to the Board of e-Therapeutics plc. She brings a wealth of relevant experience as we look to build the Company going forward. I would also like to thank Brad Hoy on behalf of the Company for his service and commitment over the last nine years and also to personally thank him for his support during my tenure as Chairman."

The following additional information is provided in accordance with Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for Companies.

Christine Helen Soden, aged 60, has no shareholding in e-Therapeutics plc. Her current and previous directorships or partnerships are detailed below:

Current directorships and partnerships:

Acacia Pharma Group Limited

Acacia Pharma Limited

Fertility Focus Limited

Futurenova Limited

Past directorships and partnerships held within the last 5 years:

CT2 Holdings Limited

CT2 Limited

Electrical Geodesics, Inc.

There is no further information to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies.

-Ends-

For further information, please contact:

 
 e-Therapeutics plc           Tel: [phone] 
  Iain Ross, Chairman          883 125 
  Ray Barlow, CEO              www.etherapeutics.co.uk 
  Steve Medlicott, CFO 
 Numis Securities Limited     Tel: +44 (0) 207 
  Michael Meade/Freddie        260 1000 
  Barnfield                    www.numis.com 
  (Nominated Adviser) 
  James Black (Corporate 
  Broking) 
 Instinctif Partners          Tel: +44 (0) 207 
  Melanie Toyne Sewell/Alex    457 2020 
  Shaw                         Email: [e-mail] 
 

Notes to Editors

About e-Therapeutics plc

e-Therapeutics is an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.

Its novel methodology and Discovery Engine allow the Company to discover new and better drugs in a more efficient and effective way.

For more information about the Company, please visit www.etherapeutics.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUASURBNAROUA

(END) Dow Jones Newswires

November 01, 2017 03:00 ET (07:00 GMT)